JENSCARE-B (09877) saw its shares rise more than 8%. As of the time of writing, the stock was up 8.49%, trading at HK$9.2 with a turnover of HK$1.0444 million. The catalyst for the move was an announcement from JENSCARE this morning stating that its transcatheter aortic valve replacement system, Ken-Valve, and its transvascular tricuspid valve replacement system, LuX-Valve Plus, have recently received registration approval from New Zealand's Medicines and Medical Devices Safety Authority. The company is actively advancing the commercialization of both products in New Zealand. The announcement highlighted that, due to their design advantages, completed registration clinical trials, and ongoing therapy promotion efforts, Ken-Valve and LuX-Valve Plus have already gained broad market recognition. With the registration approval from New Zealand's regulatory authority for these two key products, the company will accelerate the global commercialization of its product portfolio to further achieve its long-term strategic objectives.